Decibel Therapeutics Announces Publication of Foundational Study of Noise-related Inner Ear Damage
September 30, 2021 17:42 ET
|
Decibel Therapeutics, Inc.
BOSTON, Sept. 30, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore...
Decibel Therapeutics Receives Orphan Drug and Rare Pediatric Disease Designations for DB-OTO for the Treatment of Otoferlin-Related Congenital Hearing Loss
September 09, 2021 07:30 ET
|
Decibel Therapeutics, Inc.
BOSTON, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore...
Decibel Therapeutics to Present at Upcoming Investor Conferences
September 02, 2021 07:30 ET
|
Decibel Therapeutics, Inc.
BOSTON, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore...
Decibel Therapeutics Appoints Cynthia Hu as Chief Legal Officer and Corporate Secretary
August 18, 2021 07:30 ET
|
Decibel Therapeutics, Inc.
BOSTON, Aug. 18, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and...
Decibel Therapeutics Expands World-Class Scientific Advisory Board
May 24, 2021 16:15 ET
|
Decibel Therapeutics, Inc.
BOSTON, May 24, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and...
Decibel Therapeutics to Present at the UBS Global Healthcare Virtual Conference
May 19, 2021 08:00 ET
|
Decibel Therapeutics, Inc.
BOSTON, May 19, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and...
Decibel Therapeutics Reports First Quarter 2021 Financial Results and Corporate Update
May 13, 2021 17:05 ET
|
Decibel Therapeutics, Inc.
– Established cGMP manufacturing and development agreement with Catalent for otoferlin dual-vector gene therapy, DB-OTO – – Successfully completed the second tranche of an oversubscribed Series D...
Decibel Therapeutics to Present at the American Society of Gene and Cell Therapy 24th Annual Meeting
April 28, 2021 08:00 ET
|
Decibel Therapeutics, Inc.
BOSTON, April 28, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore...
Decibel Therapeutics to Present at the 20th Annual Needham Virtual Healthcare Conference
April 08, 2021 08:00 ET
|
Decibel Therapeutics, Inc.
BOSTON, April 08, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore...
Decibel Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Corporate Update
March 29, 2021 16:05 ET
|
Decibel Therapeutics, Inc.
-Successfully completed an oversubscribed Series D financing and upsized Initial Public Offering raising approximately $220.1M in gross proceeds- -Established development and manufacturing agreement...